News & Insights

Gunderson Dettmer co-sponsored the Longwood Healthcare Leaders Boston CEO Summit 2025, a two-day, invitation-only conference that convenes approximately 250 biopharma CEOs, R&D executives, government officials, life science investors, and leading academics for off-the-record discussions

Watch the Exclusive Premiere on What’s Next in Biotech with Gunderson Partner and Chair of Life Sciences Tim Ehrlich and Venrock Managing Partner Bryan Roberts

Gunderson Dettmer partner, Tim Ehrlich, to moderate a panel at the annual Genesis London Conference

Forbes recognizes 22 individuals across 13 Gunderson Dettmer clients in the 15th annual Forbes 30 Under 30 United States list, where clients were featured for their innovation, success, and leadership in categories including AI, Energy and Green Tech, Finance, Healthcare, and more

Contineum Therapeutics, a clinical-stage biopharmaceutical company, announces the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share.

Hims & Hers, the leading health and wellness platform, announces the acquisition of Livewell, a Canadian digital health platform

LMG Life Sciences recognizes Gunderson Dettmer with Impact Deal of the Year and names Boston associate Joel Diamond the US Rising Star—Financial and Corporate in its 2025 Life Sciences Americas Awards

Gunderson Dettmer ranks as the most active law firm in the world for the second quarter in a row in PitchBook’s Q2 2025 Global League Tables, with 336 financings across the globe exceeding $25 billion in value